<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5421960</article-id><article-id pub-id-type="pmid">27788498</article-id><article-id pub-id-type="publisher-id">12900</article-id><article-id pub-id-type="doi">10.18632/oncotarget.12900</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research Paper</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Li</surname><given-names>Jie</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Lu</surname><given-names>Ming</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Lu</surname><given-names>Zhihao</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Zhongwu</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yiqiang</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Jian</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xiaotian</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xicheng</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gong</surname><given-names>Jifang</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shen</surname><given-names>Lin</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> Department of GI Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University School of Oncology, Beijing Cancer Hospital &amp; Institute, Beijing, China</aff><aff id="A2"><sup>2</sup> Department of Pathology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University School of Oncology, Beijing Cancer Hospital &amp; Institute, Beijing, China</aff><aff id="A3"><sup>3</sup> Center of clinical oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China</aff><author-notes><corresp id="cor1"><bold><italic>Correspondence to:</italic></bold><italic>Lin Shen,</italic><email>lin100@medmail.com.cn</email></corresp></author-notes><pub-date pub-type="collection"><day>11</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>25</day><month>10</month><year>2016</year></pub-date><volume>8</volume><issue>15</issue><fpage>25669</fpage><lpage>25678</lpage><history><date date-type="received"><day>21</day><month>2</month><year>2016</year></date><date date-type="accepted"><day>16</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: © 2017 Li et al.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License</ext-link> (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>There have been very few prospective studies of first-line chemotherapy on advanced gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC). </plain></SENT>
<SENT sid="2" pm="."><plain>This phase II study assessed the activity and safety of irinotecan plus cisplatin (IP) followed by octreotide long-acting release (LAR) maintenance treatment in advanced GEP-NEC. </plain></SENT>
<SENT sid="3" pm="."><plain>Forty patients were treated and eighteen patients (45.0%) had a partial response. </plain></SENT>
<SENT sid="4" pm="."><plain>The median progression-free survival (PFS) and overall survival (OS) were 5.7 months and 12.9 months, respectively. </plain></SENT>
<SENT sid="5" pm="."><plain>Because GEP-NECs are heterogeneous, a subgroup analysis was conducted by dividing all patients into a high proliferation neuroendocrine tumor (NET) group (well differentiated neuroendocrine neoplasms with a Ki-67 level between 20-60%) or a poorly differentiated NEC (PDNEC) group. </plain></SENT>
<SENT sid="6" pm="."><plain>Compared with the PDNEC group, the patients in high proliferation NET group had a lower response rate (0% versus 51.4%) but longer PFS (8.9 versus 5.7 months) and received more octreotide LAR treatment (median cycles, 7 versus 3). </plain></SENT>
<SENT sid="7" pm="."><plain>The most common toxicities included grade 3/4 leukopenia/neutropenia (60%), nausea/vomiting (17.5%) and diarrhea (12.5%). </plain></SENT>
<SENT sid="8" pm="."><plain>Therefore, IP is an active regimen in patients with advanced GEP-PDNEC and should probably not be given to patients with advanced high proliferative NET. </plain></SENT>
<SENT sid="9" pm="."><plain>The benefit of octreotide LAR maintenance therapy on high proliferation NETs requires further study. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>gastroenteropancreatic neuroendocrine carcinomas</kwd><kwd>irinotecan</kwd><kwd>cisplatin</kwd><kwd>octreotide long-acting release</kwd><kwd>heterogeneous</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec id="s1"><title><text><SENT sid="10" pm="."><plain>INTRODUCTION </plain></SENT>
</text></title><p><text><SENT sid="11" pm="."><plain>Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of neoplasms arising from the diffuse neuroendocrine system. </plain></SENT>
<SENT sid="12" pm="."><plain>According to the 2010 World Health Organization (WHO) classification [1], neuroendocrine tumors are classified histologically based on tumor differentiation (well or poorly differentiated) and tumor grade (grades 1-3). </plain></SENT>
<SENT sid="13" pm="."><plain>Poorly differentiated or grade 3 neuroendocrine tumors, which are also called neuroendocrine carcinoma (NEC), have a mitotic count exceeding 20/10 high-power field (HPF) and/or a Ki-67 index exceeding 20%. </plain></SENT>
</text></p><p><text><SENT sid="14" pm="."><plain>Although previously regarded as rare, the incidence of GEP-NEC has recently started to increase [2–6], likely due to more precise pathologic classification. </plain></SENT>
<SENT sid="15" pm="."><plain>Most GEP-NECs are metastatic at the time of diagnosis, and the patient prognosis is always dismal [7, 8]. </plain></SENT>
<SENT sid="16" pm="."><plain>Guidelines for the treatment of advanced GEP-NEC advocate the use of platinum-based chemotherapy combined with etoposide [9–12]. </plain></SENT>
<SENT sid="17" pm="."><plain>However, until recently, only a few small first-line studies have been reported, and the objective response rate (ORR) to the EP regimen for advanced GEP-NECs varies greatly from 14% to 67% [13–15]. </plain></SENT>
</text></p><p><text><SENT sid="18" pm="."><plain>In 2002, a clinical trial demonstrated that an irinotecan/cisplatin (IP) regimen achieved better survival than the EP regimen in extensive small cell lung cancer (SCLC) patients [16]. </plain></SENT>
<SENT sid="19" pm="."><plain>Our retrospective study has also revealed that the ORR of IP chemotherapy was 57.1 %, with a disease control rate of 78.6 % in advanced GEP-NEC patients [17]. </plain></SENT>
<SENT sid="20" pm="."><plain>Although quite chemo-sensitive, advanced GEP-NECs are always aggressive with short progression-free survival (PFS) and overall survival (OS) times. </plain></SENT>
<SENT sid="21" pm="."><plain>A procedure that maintains a good response to IP treatment and improves the OS has yet to be determined. </plain></SENT>
</text></p><p><text><SENT sid="22" pm="."><plain>Somatostatin analogs, initially used for the treatment of carcinoid syndrome [18–20], have recently been shown to have anti-proliferative activity [21–23]. </plain></SENT>
<SENT sid="23" pm="."><plain>In our retrospective study [17], octreotide long-acting release (LAR) was administered as maintenance treatment for patients in which the disease was controlled after an irinotecan/cisplatin regimen. </plain></SENT>
<SENT sid="24" pm="."><plain>All patients tolerated the octreotide LAR treatment well. </plain></SENT>
<SENT sid="25" pm="."><plain>The median number of cycles of octreotide LAR was 4.5 (3-20 cycles), which showed that octreotide LAR may be a good option for maintenance treatment. </plain></SENT>
</text></p><p><text><SENT sid="26" pm="."><plain>Hence, we conducted this phase II trial (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> Identifier: NCT01480986) with the aim of investigating the activity and safety of IP treatment and subsequent octreotide LAR treatment as a first-line approach in the treatment of patients with advanced GEP-NECs. </plain></SENT>
</text></p></sec></SecTag><SecTag type="RESULTS"><sec id="s2"><title><text><SENT sid="27" pm="."><plain>RESULTS </plain></SENT>
</text></title><sec id="s2_1"><title><text><SENT sid="28" pm="."><plain>Patient characteristics </plain></SENT>
</text></title><p><text><SENT sid="29" pm="."><plain>The study was activated in August 2011 and closed to patient accrual in December 2013. </plain></SENT>
<SENT sid="30" pm="."><plain>Forty patients were enrolled. </plain></SENT>
<SENT sid="31" pm="."><plain>Table 1 shows the characteristics of the enrolled patients. </plain></SENT>
<SENT sid="32" pm="."><plain>In order to guarantee the quality of the trial, all the 5 patients with unknown primary tumor had been reviewed and approved by the multidisciplinary team (MDT) during the screening period. </plain></SENT>
<SENT sid="33" pm="."><plain>Last follow-up was in December 2014. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title><text><SENT sid="34" pm="."><plain>Patient demographics and clinical characteristics </plain></SENT>
</text></title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="35" pm="."><plain>Variables </plain></SENT>
</text></th><th align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="36" pm="."><plain>Number of patients </plain></SENT>
</text></th><th align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="37" pm="."><plain>Proportion (%) </plain></SENT>
</text></th></tr></thead><tbody><tr><td colspan="3" align="left" valign="middle" rowspan="1"><text><SENT sid="38" pm="."><plain>Gender </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="39" pm="."><plain> Male </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="40" pm="."><plain>30 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="41" pm="."><plain>75.0 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="42" pm="."><plain> Female </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="43" pm="."><plain>10 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="44" pm="."><plain>25.0 </plain></SENT>
</text></td></tr><tr><td colspan="3" align="left" valign="middle" rowspan="1"><text><SENT sid="45" pm="."><plain>Age [median (range)], 56.5 (30–77) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="46" pm="."><plain> &lt;59 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="47" pm="."><plain>25 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="48" pm="."><plain>62.5 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="49" pm="."><plain> ≥60 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="50" pm="."><plain>15 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="51" pm="."><plain>37.5 </plain></SENT>
</text></td></tr><tr><td colspan="3" align="left" valign="middle" rowspan="1"><text><SENT sid="52" pm="."><plain>Karnofsky performance score(KPS) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="53" pm="."><plain> &lt;90 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="54" pm="."><plain>19 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="55" pm="."><plain>47.5 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="56" pm="."><plain> ≥90 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="57" pm="."><plain>21 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="58" pm="."><plain>52.5 </plain></SENT>
</text></td></tr><tr><td colspan="3" align="left" valign="middle" rowspan="1"><text><SENT sid="59" pm="."><plain>Location of primary tumor </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="60" pm="."><plain> Stomach </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="61" pm="."><plain>15 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="62" pm="."><plain>37.5 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="63" pm="."><plain> Esophagus </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="64" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="65" pm="."><plain>20.0 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="66" pm="."><plain> Pancreas </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="67" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="68" pm="."><plain>15.0 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="69" pm="."><plain> Colorectum </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="70" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="71" pm="."><plain>10.0 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="72" pm="."><plain> Small intestine </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="73" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="74" pm="."><plain>5.0 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="75" pm="."><plain> Unknown primary origin </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="76" pm="."><plain>5 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="77" pm="."><plain>12.5 </plain></SENT>
</text></td></tr><tr><td colspan="3" align="left" valign="middle" rowspan="1"><text><SENT sid="78" pm="."><plain>Histology </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="79" pm="."><plain> Small cell NEC </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="80" pm="."><plain>20 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="81" pm="."><plain>50.0 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="82" pm="."><plain> Large cell NEC </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="83" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="84" pm="."><plain>20.0 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="85" pm="."><plain> MANEC </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="86" pm="."><plain>7 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="87" pm="."><plain>17.5 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="88" pm="."><plain> High proliferation NET </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain>5 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="90" pm="."><plain>12.5 </plain></SENT>
</text></td></tr><tr><td colspan="3" align="left" valign="middle" rowspan="1"><text><SENT sid="91" pm="."><plain>Immunohistochemistry(positive/total) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain> Synaptophysin </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="93" pm="."><plain>36/40 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="94" pm="."><plain>90.0 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="95" pm="."><plain> Chromogranin A </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>25/39 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="97" pm="."><plain>64.1 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain> CD56 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="99" pm="."><plain>25/39 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="100" pm="."><plain>64.1 </plain></SENT>
</text></td></tr><tr><td colspan="3" align="left" valign="middle" rowspan="1"><text><SENT sid="101" pm="."><plain>Ki-67 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="102" pm="."><plain> ≥ 75% </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="103" pm="."><plain>21 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="104" pm="."><plain>52.5 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="105" pm="."><plain>50-74% </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="106" pm="."><plain>9 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="107" pm="."><plain>22.5 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="108" pm="."><plain>20-49% </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="109" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="110" pm="."><plain>20.0 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="111" pm="."><plain> Unknown </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="112" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain>5.0 </plain></SENT>
</text></td></tr><tr><td colspan="3" align="left" valign="middle" rowspan="1"><text><SENT sid="114" pm="."><plain>Carcinoid syndrome </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain> Yes </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>7.5 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain> No </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>37 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>92.5 </plain></SENT>
</text></td></tr><tr><td colspan="3" align="left" valign="middle" rowspan="1"><text><SENT sid="121" pm="."><plain>Octreotide scanning </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain> Positive </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>19 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="124" pm="."><plain>47.5 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain> Negative </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>20 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain>50.0 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="128" pm="."><plain> Unknown </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>2.5 </plain></SENT>
</text></td></tr><tr><td colspan="3" align="left" valign="middle" rowspan="1"><text><SENT sid="131" pm="."><plain>Stage </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain> Locally advanced </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>5 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>12.5 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain> Metastatic </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>35 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>87.5 </plain></SENT>
</text></td></tr><tr><td colspan="3" align="left" valign="middle" rowspan="1"><text><SENT sid="138" pm="."><plain>Metastasis </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain> Liver </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>25 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>62.5 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain> Lung </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="143" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>7.5 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain> Bone </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>5 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>12.5 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="148" pm="."><plain> Distant lymph nodes </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>29 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>72.5 </plain></SENT>
</text></td></tr><tr><td colspan="3" align="left" valign="middle" rowspan="1"><text><SENT sid="151" pm="."><plain>Serum NSE level before treatment </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain> &lt;50ng/ml </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>21 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>52.5 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain> ≥50ng/ml </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="156" pm="."><plain>17 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="157" pm="."><plain>42.5 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="158" pm="."><plain> unknown </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>5 </plain></SENT>
</text></td></tr><tr><td colspan="3" align="left" valign="middle" rowspan="1"><text><SENT sid="161" pm="."><plain>Serum LDH level before treatment </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain> &lt;300U/ml </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>29 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain>72.5 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain> ≥300U/ml </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>11 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>27.5 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><text><SENT sid="168" pm="."><plain>*Abbreviations: NEC=neuroendocrine carcinoma; MANEC=mixed adenoneuroendocrine carcinoma; NET= neuroendocrine tumor; NSE= neuron-specific enolase; LDH= lactic dehydrogenase. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="s2_2"><title><text><SENT sid="169" pm="."><plain>Treatment received </plain></SENT>
</text></title><p><text><SENT sid="170" pm="."><plain>The total number of IP regimen cycles for all the paitents was 155, with a median of 4 for each patient. </plain></SENT>
<SENT sid="171" pm="."><plain>Ten patients (25.0%) received only one cycle of IP treatment due to rapid tumor progression (one patient) and treatment-related toxicity (two patients with febrile neutropenia, grade 3 thrombocytopenia and grade 3 diarrhea and seven patients with a treatment delay of more than 2 weeks due to toxicity). </plain></SENT>
<SENT sid="172" pm="."><plain>Three patients who had locally advanced disease received an R0 resection after systemic treatment. </plain></SENT>
<SENT sid="173" pm="."><plain>Seventeen patients (42.5%) completed the planned six cycles of IP chemotherapy, and 12 went on to receive octreotide LAR according to the protocol. </plain></SENT>
<SENT sid="174" pm="."><plain>Four patients received octreotide LAR as maintenance treatment following discontinuing chemotherapy due to severe toxicities. </plain></SENT>
<SENT sid="175" pm="."><plain>Table 2 shows the characteristics and clinical outcomes of patients with octreotide LAR maintenance treatment. </plain></SENT>
<SENT sid="176" pm="."><plain>The median number of octreotide LAR cycles was 3 (1-25 cycles). </plain></SENT>
<SENT sid="177" pm="."><plain>Due to a change in the pharmaceutical dosage forms in China, 6 patients received octreotide LAR (30 mg). </plain></SENT>
<SENT sid="178" pm="."><plain>Of the 16 patients who received maintenance octreotide LAR, 1 patient received only one dose of octreotide LAR due to intolerable diarrhea, 2 patients discontinued the drug due to financial problems, and the remaining 13 patients continued octreotide LAR treatment until the disease progressed. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title><text><SENT sid="179" pm="."><plain>Characteristics and clinical outcomes of patients with advanced GEP-NEC receiving octreotide LAR maintenance treatment </plain></SENT>
</text></title></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" align="left" valign="middle" colspan="1"><text><SENT sid="180" pm="."><plain>No </plain></SENT>
</text></th><th rowspan="2" align="left" valign="middle" colspan="1"><text><SENT sid="181" pm="."><plain>Gender/age </plain></SENT>
</text></th><th rowspan="2" align="left" valign="middle" colspan="1"><text><SENT sid="182" pm="."><plain>Histology </plain></SENT>
</text></th><th rowspan="2" align="left" valign="middle" colspan="1"><text><SENT sid="183" pm="."><plain>Octreatidescan </plain></SENT>
</text></th><th rowspan="2" align="left" valign="middle" colspan="1"><text><SENT sid="184" pm="."><plain>Primarysite </plain></SENT>
</text></th><th rowspan="2" align="left" valign="middle" colspan="1"><text><SENT sid="185" pm="."><plain>Metastaticsites </plain></SENT>
</text></th><th rowspan="2" align="left" valign="middle" colspan="1"><text><SENT sid="186" pm="."><plain>IPcycles </plain></SENT>
</text></th><th rowspan="2" align="left" valign="middle" colspan="1"><text><SENT sid="187" pm="."><plain>IPresponse </plain></SENT>
</text></th><th colspan="3" align="left" valign="middle" rowspan="1"><text><SENT sid="188" pm="."><plain>Octreotide LAR </plain></SENT>
</text></th><th rowspan="2" align="left" valign="middle" colspan="1"><text><SENT sid="189" pm="."><plain>PFS(m) </plain></SENT>
</text></th></tr><tr><th align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>Cycles </plain></SENT>
</text></th><th align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain>Dosage(mg) </plain></SENT>
</text></th><th align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>Reasons for interruption </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>F/63 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>L-NEC </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="196" pm="."><plain>Positive </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="197" pm="."><plain>Pancreas </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="198" pm="."><plain>Liver, LNs </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="199" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="200" pm="."><plain>NA </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="201" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="202" pm="."><plain>20 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="203" pm="."><plain>PD </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="204" pm="."><plain>3.27 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="205" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="206" pm="."><plain>M/55 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="207" pm="."><plain>L-NEC </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="208" pm="."><plain>Positive </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="209" pm="."><plain>colorectum </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="210" pm="."><plain>Cervical LNs </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="211" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="212" pm="."><plain>PR </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="213" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="214" pm="."><plain>20 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="215" pm="."><plain>Financial problem </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>14 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="217" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="218" pm="."><plain>F/66 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="219" pm="."><plain>S-NEC </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>Negative </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>Stomach </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>Liver, Lung, LNs </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="223" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="224" pm="."><plain>PR </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>20 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>PD </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="228" pm="."><plain>5.63 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="229" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>M/56 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>S-NEC </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>Positive </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>Unknown </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>Pelvic and inguinal LNs </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>PR </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>25 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>20 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>PD </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>26.5 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>5 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>M/59 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>S-NEC </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>Negative </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>Unknown </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>Liver, Bone, LNs </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>PR </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>20 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>PD </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>6.9 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>M/51 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>MANEC </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>Negative </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>Esophagus </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>Lung, Bone, LNs </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>SD </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>20 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>PD </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>4.57 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>7 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>M/57 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>MANEC </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>Positive </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>Stomach </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="270" pm="."><plain>Liver, LNs </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="271" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="272" pm="."><plain>PR </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="274" pm="."><plain>20 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>PD </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>4.53 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>F/48 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="279" pm="."><plain>MANEC </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="280" pm="."><plain>Negative </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="281" pm="."><plain>Stomach </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>Celiac and retroperitoneal LNs </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="284" pm="."><plain>PR </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="285" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="286" pm="."><plain>20 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="287" pm="."><plain>PD </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="288" pm="."><plain>12.3 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="289" pm="."><plain>9 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="290" pm="."><plain>M/67 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="291" pm="."><plain>MANEC </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="292" pm="."><plain>Negative </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="293" pm="."><plain>Stomach </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="294" pm="."><plain>Liver </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="295" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="296" pm="."><plain>PR </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="297" pm="."><plain>5 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="298" pm="."><plain>20 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="299" pm="."><plain>PD </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="300" pm="."><plain>7.37 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="301" pm="."><plain>10 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="302" pm="."><plain>M/30 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="303" pm="."><plain>H-NET </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="304" pm="."><plain>Positive </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="305" pm="."><plain>Pancreas </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="306" pm="."><plain>Liver, Bone, LNs </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="307" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="308" pm="."><plain>SD </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="309" pm="."><plain>5 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="310" pm="."><plain>20 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="311" pm="."><plain>PD </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="312" pm="."><plain>8.93 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="313" pm="."><plain>11 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="314" pm="."><plain>M/54 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="315" pm="."><plain>MANEC </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="316" pm="."><plain>Positive </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="317" pm="."><plain>Stomach </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="318" pm="."><plain>Supraclavicular Celiac, retroperitoneal and pelvic LNs </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="319" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="320" pm="."><plain>PR </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="321" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="322" pm="."><plain>30 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="323" pm="."><plain>PD </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="324" pm="."><plain>3.7 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="325" pm="."><plain>12 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="326" pm="."><plain>M/54 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="327" pm="."><plain>L-NEC </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="328" pm="."><plain>Positive </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="329" pm="."><plain>Pancreas </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="330" pm="."><plain>Liver, LNs </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="331" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="332" pm="."><plain>PR </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="333" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="334" pm="."><plain>30 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="335" pm="."><plain>Severe diarrhea </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="336" pm="."><plain>5.6 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="337" pm="."><plain>13 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="338" pm="."><plain>F/63 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="339" pm="."><plain>S-NEC </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="340" pm="."><plain>Negative </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="341" pm="."><plain>Unknown </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="342" pm="."><plain>Lung, LNs </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="343" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="344" pm="."><plain>PR </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="345" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="346" pm="."><plain>30 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="347" pm="."><plain>PD </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="348" pm="."><plain>5.27 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="349" pm="."><plain>14 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="350" pm="."><plain>M/48 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="351" pm="."><plain>S-NEC </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="352" pm="."><plain>Positive </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="353" pm="."><plain>Pancreas </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="354" pm="."><plain>Liver, LNs </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="355" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="356" pm="."><plain>SD </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="357" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="358" pm="."><plain>30 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="359" pm="."><plain>PD </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="360" pm="."><plain>7.6 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="361" pm="."><plain>15 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="362" pm="."><plain>M/56 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="363" pm="."><plain>S-NEC </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="364" pm="."><plain>Positive </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="365" pm="."><plain>Stomach </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="366" pm="."><plain>Liver, LNs </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="367" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="368" pm="."><plain>PR </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="369" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="370" pm="."><plain>30 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="371" pm="."><plain>PD </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="372" pm="."><plain>8.17 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="373" pm="."><plain>16 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="374" pm="."><plain>F/55 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="375" pm="."><plain>H-NET </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="376" pm="."><plain>Negative </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="377" pm="."><plain>Stomach </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="378" pm="."><plain>Liver, LNs </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="379" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="380" pm="."><plain>SD </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="381" pm="."><plain>9 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="382" pm="."><plain>30 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="383" pm="."><plain>Financial problem </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="384" pm="."><plain>14.9 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><text><SENT sid="385" pm="."><plain>*Abbreviations: F= female; M= male; L-NEC= large cell neuroendocrine carcinoma; S-NEC= small cell neuroendocrine carcinoma; H-NET= high proliferation neuroendocrine tumor; MANEC= mixed adenoneuroendocrine carcinoma; LN= lymph node; IP= irinotecan plus cisplatin; SD= stable disease; PR= partial response; LAR= long-acting release; PD=progression disease; NA= Not applicable; m= month. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="386" pm="."><plain>After disease progression, the patients were given a variety of palliative treatments including radiotherapy (5 patients, 12.5%), octreotide LAR treatment (2 patients, 5.0%), transcatheter arterial chemoembolization (7 patients, 17.5%) and salvage chemotherapy (9 patients, 22.5%). </plain></SENT>
<SENT sid="387" pm="."><plain>Salvage chemotherapy regimens consisted of combined chemotherapy including irinotecan with platinum (5 patients, who had got PR or MR in the first line IP treatment), etoposide with platinum, and temozolomide with capecitabine; the single agents included paclitaxel, irinotecan, etoposide and capecitabine. </plain></SENT>
</text></p></sec><sec id="s2_3"><title><text><SENT sid="388" pm="."><plain>Response to treatment </plain></SENT>
</text></title><p><text><SENT sid="389" pm="."><plain>A total of 32 patients were evaluable for tumor response. </plain></SENT>
<SENT sid="390" pm="."><plain>(Table 3) No patient achieved a complete response (CR); eighteen (18/40, 45.0%) patients had a partial response (PR) and 10 (10/40, 25.0%) had stable disease (SD). </plain></SENT>
<SENT sid="391" pm="."><plain>The disease control rate (DCR) was 70.0%. </plain></SENT>
<SENT sid="392" pm="."><plain>The response rate to IP treatment in esophageal NEC, gastric NEC, and pancreatic NEC was 62.5%, 40.0% and 16.7%, respectively (p = 0.253). </plain></SENT>
<SENT sid="393" pm="."><plain>The median PFS was 5.7 months (95% confidence interval: 3.8-7.6 months), and the median OS was 12.9 months (95% confidence interval: 10.5-15.4 months) for the entire group. </plain></SENT>
<SENT sid="394" pm="."><plain>(Figure 1) For the 37 patients who haven't received surgery following IP chemotherapy, the median PFS was 5.6 months (95% confidence interval: 4.3-6.9 months), and the median OS was 12.8 months (95% confidence interval: 10.7-15.0 months). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title><text><SENT sid="395" pm="."><plain>Clinical outcomes of IP chemotherapy in patients with advanced GEP-NEC by different histological subtypes </plain></SENT>
</text></title></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="396" pm="."><plain>Histology </plain></SENT>
</text></th><th colspan="6" align="center" valign="middle" rowspan="1"><text><SENT sid="397" pm="."><plain>Response to IP regimen </plain></SENT>
</text></th><th rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="398" pm="."><plain>PFS(months) </plain></SENT>
</text></th></tr><tr><th align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="399" pm="."><plain>No.of CR (%) </plain></SENT>
</text></th><th align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="400" pm="."><plain>No.ofPR (%) </plain></SENT>
</text></th><th align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="401" pm="."><plain>No.ofSD (%) </plain></SENT>
</text></th><th align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="402" pm="."><plain>No.of PD (%) </plain></SENT>
</text></th><th align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="403" pm="."><plain>No.of NA (%) </plain></SENT>
</text></th><th align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="404" pm="."><plain>Disease control rate (%) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="405" pm="."><plain>Small cell NEC (n= 20) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="406" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="407" pm="."><plain>11 (55.0) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="408" pm="."><plain>3 (15.0) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="409" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="410" pm="."><plain>6 (30.0) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="411" pm="."><plain>70.0 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="412" pm="."><plain>6.9 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="413" pm="."><plain>Large cell NEC (n= 8) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="414" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="415" pm="."><plain>3 (37.5) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="416" pm="."><plain>2 (25.0) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="417" pm="."><plain>2 (25.0) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="418" pm="."><plain>1 (12.5) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="419" pm="."><plain>62.5 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="420" pm="."><plain>5.6 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="421" pm="."><plain>MANEC (n= 7) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="422" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="423" pm="."><plain>4 (57.1) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="424" pm="."><plain>1 (14.3) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="425" pm="."><plain>1 (14.3) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="426" pm="."><plain>1 (14.3) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="427" pm="."><plain>71.4 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="428" pm="."><plain>4.5 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="429" pm="."><plain>High proliferation NET (n= 5) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="430" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="431" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="432" pm="."><plain>4 (80.0) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="433" pm="."><plain>1 (20.0) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="434" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="435" pm="."><plain>80.0 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="436" pm="."><plain>8.9 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="437" pm="."><plain>All patients (n= 40) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="438" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="439" pm="."><plain>18 (45.0) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="440" pm="."><plain>10 (25.0) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="441" pm="."><plain>4 (10.0) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="442" pm="."><plain>8 (20.0) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="443" pm="."><plain>70.0 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="444" pm="."><plain>5.7 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><text><SENT sid="445" pm="."><plain>*Abbreviations: IP= irinotecan plus cisplatin; PFS=progression-free survival; CR= complete response; PR= partial response; SD= stable disease; PD= progression disease; NA= Not applicable; NEC= neuroendocrine carcinoma; MANEC= mixed adenoneuroendocrine carcinoma; NET= neuroendocrine tumor. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="FIG"><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title><text><SENT sid="446" pm="."><plain>Overall survival (continuous line, median 12.9 months) and progression-free survival (dotted line, median 5.7 months) in the 40 patients with advanced GEP-NEC after IP treatment </plain></SENT>
</text></title></caption><graphic xlink:href="oncotarget-08-25669-g001"/></fig></SecTag><p><text><SENT sid="447" pm="."><plain>According to the 2013 Chinese gastrointestinal and pancreatic neuroendocrine neoplasms pathologic consensus [24], compared with the patients in poorly differentiated NEC (PDNEC) group, the patients with high proliferation neuroendocrine tumor (NET) had a lower ORR (0% versus 51.4%, p = 0.053) but longer PFS (8.9 versus 5.7 months) and received more octreotide LAR treatment (median cycles, 7 versus 3). </plain></SENT>
<SENT sid="448" pm="."><plain>(Table 2 and Table 3) </plain></SENT>
</text></p></sec><sec id="s2_4"><title><text><SENT sid="449" pm="."><plain>Toxicities </plain></SENT>
</text></title><p><text><SENT sid="450" pm="."><plain>The IP regimen-related toxicities are summarized in Table 4. </plain></SENT>
<SENT sid="451" pm="."><plain>Grade 3/4 leukopenia/neutropenia was observed in 24 patients (60.0%), and 3 patients (7.5%) experienced febrile neutropenia. </plain></SENT>
<SENT sid="452" pm="."><plain>Grade 3/4 thrombocytopenia occurred in 2 patients (5.0%). </plain></SENT>
<SENT sid="453" pm="."><plain>No grade 3/4 hematological toxicity was observed during the octreotide LAR maintenance treatment. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title><text><SENT sid="454" pm="."><plain>Chemotherapy-related toxicity after IP chemotherapy (N = 40; 155 treatment cycles) </plain></SENT>
</text></title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="455" pm="."><plain>Toxicity </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="456" pm="."><plain>All gradesPatients, n (%) </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="457" pm="."><plain>Grade 3Patients, n (%) </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="458" pm="."><plain>Grade 4Patients, n (%) </plain></SENT>
</text></th></tr></thead><tbody><tr><td colspan="4" align="left" valign="middle" rowspan="1"><text><SENT sid="459" pm="."><plain>Hematologic </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="460" pm="."><plain> Leukopenia/Neutropenia </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="461" pm="."><plain>35 (87.5) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="462" pm="."><plain>14 (35.0) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="463" pm="."><plain>10 (25.0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="464" pm="."><plain> Anemia </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="465" pm="."><plain>20 (50.0) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="466" pm="."><plain>1 (2.5) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="467" pm="."><plain>0 (0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="468" pm="."><plain> Thrombocytopenia </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="469" pm="."><plain>14 (35.0) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="470" pm="."><plain>2 (5.0) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="471" pm="."><plain>0 (0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="472" pm="."><plain> Neutropenic fever </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="473" pm="."><plain>3 (7.5) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="474" pm="."><plain>NA </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="475" pm="."><plain>NA </plain></SENT>
</text></td></tr><tr><td colspan="4" align="left" valign="middle" rowspan="1"><text><SENT sid="476" pm="."><plain>Non-hematologic </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="477" pm="."><plain> AST/ALT </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="478" pm="."><plain>6 (15.0) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="479" pm="."><plain>0 (0) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="480" pm="."><plain>0 (0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="481" pm="."><plain> Fatigue </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="482" pm="."><plain>18 (45.0) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="483" pm="."><plain>1 (2.5) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="484" pm="."><plain>0 (0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="485" pm="."><plain> Neurological sensory </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="486" pm="."><plain>6 (15.0) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="487" pm="."><plain>0 (0) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="488" pm="."><plain>0 (0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="489" pm="."><plain> Acute cholinergic syndrome </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="490" pm="."><plain>13 (32.5) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="491" pm="."><plain>0 (0) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="492" pm="."><plain>0 (0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="493" pm="."><plain> Nausea/Vomiting </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="494" pm="."><plain>39 (97.5) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="495" pm="."><plain>7 (17.5) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="496" pm="."><plain>0 (0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="497" pm="."><plain> Diarrhea </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="498" pm="."><plain>19 (47.5) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="499" pm="."><plain>5 (12.5) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="500" pm="."><plain>0 (0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="501" pm="."><plain> Anorexia </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="502" pm="."><plain>25 (62.5) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="503" pm="."><plain>2 (5.0) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="504" pm="."><plain>0 (0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="505" pm="."><plain> Mucositis </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="506" pm="."><plain>3 (7.5) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="507" pm="."><plain>0 (0) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="508" pm="."><plain>0 (0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="509" pm="."><plain> Alopecia </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="510" pm="."><plain>17 (42.5) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="511" pm="."><plain>2 (5.0) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="512" pm="."><plain>0 (0) </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><text><SENT sid="513" pm="."><plain>*Abbreviations: AST= aspartate aminotransferase; ALT= alanine aminotransferase; NA= Not applicable. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="514" pm="."><plain>Seven patients (17.5%) suffered from grade 3 nausea/vomiting, 5 patients (12.5%) experienced grade 3 diarrhea, 2 patients (5.0%) exhibited grade 3 anorexia, 2 patients (5.0%) had grade 3 alopecia and one patient (2.5%) had severe fatigue. </plain></SENT>
<SENT sid="515" pm="."><plain>All other toxicities were mild. </plain></SENT>
<SENT sid="516" pm="."><plain>Only 1 patient experienced grade 3 diarrhea during octreotide LAR maintenance treatment. </plain></SENT>
<SENT sid="517" pm="."><plain>Due to the toxicity, nine patients (22.5%) received only one cycle of IP treatment, and fourteen patients (35%) received a dose reduction. </plain></SENT>
<SENT sid="518" pm="."><plain>No other unexpected toxicities were observed, and no treatment-related death was reported. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="s3"><title><text><SENT sid="519" pm="."><plain>DISCUSSION </plain></SENT>
</text></title><p><text><SENT sid="520" pm="."><plain>Advanced GEP-NEC patients have a poor prognosis. </plain></SENT>
<SENT sid="521" pm="."><plain>The median survival for patients receiving chemotherapy was 11 months, and for patients without chemotherapy the survival time was only 1 month [7], suggesting that those patients should be considered for chemotherapy without delay. </plain></SENT>
</text></p><p><text><SENT sid="522" pm="."><plain>Many guidelines advocate the use of platinum-based chemotherapy combined with etoposide for the treatment of patients with GEP-NEC, similar to the treatment of small cell lung cancer [9–12]. </plain></SENT>
<SENT sid="523" pm="."><plain>However, the efficacy of this treatment varies in different studies [13–15]. </plain></SENT>
<SENT sid="524" pm="."><plain>Mitry et al. [14] retrospectively analyzed the efficacy of the EP regimen in 41 NEC patients; the ORR was 41.5% (4 CR and 13 PR). </plain></SENT>
<SENT sid="525" pm="."><plain>Grade 3-4 hematological toxicity was observed in 60% of the cases with one treatment-related death. </plain></SENT>
<SENT sid="526" pm="."><plain>In a recent retrospective study [7], 252 patients with advanced GEP-NEC received cisplatin/etoposide or carboplatin/etoposide; the ORR was only 31%, and the median PFS and OS were 4 and 11 months, respectively. </plain></SENT>
<SENT sid="527" pm="."><plain>Moreover, in a Japanese retrospective study [15], 21 hepato-biliary-pancreatic NEC patients were treated with EP as a first-line chemotherapy; the ORR, median PFS and OS were only 14% and 1.8 and 5.8 months, respectively, and grade 3 or 4 neutropenia was observed in 90% of these patients. </plain></SENT>
</text></p><p><text><SENT sid="528" pm="."><plain>The JCOG9511 study demonstrated significantly longer OS in the IP arm than in the EP arm for SCLC [16]. </plain></SENT>
<SENT sid="529" pm="."><plain>In our retrospective analysis of 16 advanced GEP-NEC patients treated with IP, the median PFS and OS were 5.5 and 10.6 months, respectively [17]. </plain></SENT>
<SENT sid="530" pm="."><plain>Recently, a retrospective Japanese multicenter analysis [25] showed that for patients with advanced NEC of the digestive system including gastrointestinal tract and hepato-biliary-pancreatic system treated with IP/EP (n = 160/46), the ORR were 50%/28% and the median OS times were 13.0/7.3 months. </plain></SENT>
<SENT sid="531" pm="."><plain>A multivariate analysis among patients treated with IP or EP showed a tendency that the efficacy of IP was slightly better than that of EP (HR 0.80, 95% CI 0.48-1.33; p = 0.389). </plain></SENT>
<SENT sid="532" pm="."><plain>In this prospective study, IP as a first-line therapy for advanced stage GEP-NEC resulted in an ORR of 45.0%, a median PFS of 5.7 months and a median OS of 12.9 months, which showed that IP was an active regimen in these patients. </plain></SENT>
<SENT sid="533" pm="."><plain>Due to the IP treatment-related toxicity, the treatment interruption and dose reduction rates were high. </plain></SENT>
<SENT sid="534" pm="."><plain>Hence, dose adjustment is necessary in future studies. </plain></SENT>
</text></p><p><text><SENT sid="535" pm="."><plain>To maintain a good response to IP treatment, we searched for an antitumor agent that could be administered for a long period of time with little toxicity. </plain></SENT>
<SENT sid="536" pm="."><plain>Somatostatin analogs can exert antitumor effects by both direct and indirect mechanisms [26]. </plain></SENT>
<SENT sid="537" pm="."><plain>A placebo-controlled phase IIIB study (PROMID) [23] demonstrated that octreotide significantly lengthened the time to tumor progression compared to a placebo in patients with treatment-naive metastatic well-differentiated midgut NETs. </plain></SENT>
<SENT sid="538" pm="."><plain>CLARINET study [27] found Lanreotide was also associated with significantly prolonged progression-free survival among patients with metastatic enteropancreatic neuroendocrine tumors of grade 1 or 2 (Ki-67 &lt; 10%). </plain></SENT>
<SENT sid="539" pm="."><plain>Till now, there are no data supporting the use of somatostatin analogs in GEP-NEC [6]. </plain></SENT>
<SENT sid="540" pm="."><plain>Zarogoulidis K et al. found that long acting somatostatin analogues could be used as an additive therapy in combination to antineoplastic agents in patients with SCLC positive for somatostatin receptors [28]. </plain></SENT>
<SENT sid="541" pm="."><plain>Our retrospective analysis showed that octreotide LAR may be a good option for maintenance treatment [17]. </plain></SENT>
<SENT sid="542" pm="."><plain>In this prospective study, sixteen patients received octreotide LAR as maintenance treatment. </plain></SENT>
<SENT sid="543" pm="."><plain>The median cycle (3 cycles) of octreotide LAR treatment was less than that in our retrospective study, and 7 patients received more than three cycles of treatment. </plain></SENT>
<SENT sid="544" pm="."><plain>Among those patients, one patient with postive Octreatide-Scan received as many as 25 cycles of octreotide LAR, and two patients with negative Octreatide-Scan had 8 and 9 cycles. </plain></SENT>
<SENT sid="545" pm="."><plain>So, Octreotide LAR did have antitumor effect on the two NEC patients with negative Octreatide-Scan. </plain></SENT>
<SENT sid="546" pm="."><plain>Indirect antitumor effects of somatostatin analogs, independent of somatostatin receptors, might include inhibition of growth-promoting hormone and growth factor secretion, and antiangiogenic actions [26]. </plain></SENT>
<SENT sid="547" pm="."><plain>However, due to the insufficient numbers of the population, we can unfortunately not evaluate if there is a benefit of adding octreotide as maintenance therapy after chemotherapy. </plain></SENT>
</text></p><p><text><SENT sid="548" pm="."><plain>According to the 2010 WHO classification, there is an assumption that poorly differentiated histology and high tumor grade are equivalent. </plain></SENT>
<SENT sid="549" pm="."><plain>However, Scoazec et al. [29], who investigated a series of 104 patients with large cell GEP-NECs, found that 20% of tumors were characterized as well differentiated, despite a Ki-67 index &gt; 20%. </plain></SENT>
<SENT sid="550" pm="."><plain>In a study of 28 patients with metastatic thoracic and GEP-NECs with a Ki-67 index &gt; 20%, 42.8% of cases had histologically well differentiated tumors. </plain></SENT>
<SENT sid="551" pm="."><plain>Furthermore, they found that the proportion of patients with short survival ( &lt; 2 years) with G3 well differentiated NETs was smaller than that of patients with G3 large cell NECs (25% versus 62.5%, p = 0.049) [30]. </plain></SENT>
<SENT sid="552" pm="."><plain>In addition to the morphology, studies have indicated that a Ki-67 threshold of 55% is predictive for the response to first-line platinum-based chemotherapy. </plain></SENT>
<SENT sid="553" pm="."><plain>Patients with a Ki-67 index &lt; 55% had a lower ORR (15% versus 42%, p &lt; 0.001) to platinum-based chemotherapy, but better survival than patients with a Ki-67 index ≥ 55% (14 versus 10 months, p &lt; 0.001) [7]. </plain></SENT>
<SENT sid="554" pm="."><plain>These new findings imply that proliferation alone is not sufficient for the classification of high grade GEP-NECs, and the morphology should be incorporated into proliferative indices to correctly classify these neoplasms [31]. </plain></SENT>
</text></p><p><text><SENT sid="555" pm="."><plain>Therefore, the 2010 WHO classification may be improved to better define high grade neuroendocrine neoplasms [6, 7, 31, 32]. </plain></SENT>
<SENT sid="556" pm="."><plain>According to the recommendations of a Chinese pathologic consensus group for gastrointestinal and pancreatic neuroendocrine neoplasms [24], all of the 40 GEP-NEC tumors in this study were re-reviewed by two pathologists independently, and 5 cases were classified as high proliferation NET. </plain></SENT>
<SENT sid="557" pm="."><plain>This group of tumors shows remarkable differences compared with poorly differentiated GEP-NECs. </plain></SENT>
<SENT sid="558" pm="."><plain>First, these patients show a different response rate; patients with high proliferation NETs had a much lower ORR to IP (0%) than patients with poorly differentiated NECs (51.4%), which implies that platinum-based chemotherapy may be overused in patients with high proliferation NETs who might benefit from other systemic treatments, such as temozolomide-based or streptozotocin-based chemotherapy, everolimus, sunitinib or others [6, 33]. </plain></SENT>
<SENT sid="559" pm="."><plain>We recommend that IP treatment should only be given to G3 patients with poorly differentiated morphology. </plain></SENT>
<SENT sid="560" pm="."><plain>Second, these patients have different octreotide LAR maintenance cycles; patients with high proliferation NETs received more octreotide LAR maintenance cycles than patients with poorly differentiated NECs (median cycles, 7 versus 3 cycles). </plain></SENT>
<SENT sid="561" pm="."><plain>Although the patient numbers in these two subgroups are small, based on the biological behavior, the effect of octreotide LAR maintenance therapy on high proliferation NETs deserve further study. </plain></SENT>
<SENT sid="562" pm="."><plain>Third, the patients have different prognoses; although they have a lower ORR, patients with high proliferation NETs still had a longer PFS (8.9 versus 5.7 months). </plain></SENT>
<SENT sid="563" pm="."><plain>Therefore, it is very important to analyze the clinical diagnostic and prognostic characteristics and even the molecular pathology and genetic differences between these two subgroups to optimize the treatment of patients with advanced GEP-NECs. </plain></SENT>
</text></p><p><text><SENT sid="564" pm="."><plain>In conclusion, the current WHO high-grade NEC category might needs to be refined. </plain></SENT>
<SENT sid="565" pm="."><plain>This prospective phase II trial provides additional evidence that IP is an active regimen only in patients with advanced GEP-PDNEC and dose adjustment may be necessary due to toxicity. </plain></SENT>
<SENT sid="566" pm="."><plain>The observation suggests that IP should probably not be given to high proliferative NET. </plain></SENT>
<SENT sid="567" pm="."><plain>The benefit of octreotide LAR maintenance therapy on high proliferation NETs requires further study. </plain></SENT>
<SENT sid="568" pm="."><plain>Future research should focus on these preliminary results in large-scale, randomized trials to assess the ability to improve the treatment response and prognosis of patients with advanced GEP-NECs. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="methods" id="s4"><title><text><SENT sid="569" pm="."><plain>PATIENTS AND METHODS </plain></SENT>
</text></title><sec id="s4_1"><title><text><SENT sid="570" pm="."><plain>Study design </plain></SENT>
</text></title><p><text><SENT sid="571" pm="."><plain>This was an investigator-initiated, open-label, single-arm phase II clinical study. </plain></SENT>
<SENT sid="572" pm="."><plain>The primary end point of the study was PFS, which was defined as the time from the date of first treatment until the date of tumor progression or death. </plain></SENT>
<SENT sid="573" pm="."><plain>The secondary end points included OS, ORR and safety. </plain></SENT>
<SENT sid="574" pm="."><plain>The OS was defined as the time from the date of first treatment until the date of death. </plain></SENT>
<SENT sid="575" pm="."><plain>The study was approved by the Medical Ethics Committee of Peking University Cancer Hospital (Beijing, China) and was performed according to the Declaration of Helsinki Principles. </plain></SENT>
<SENT sid="576" pm="."><plain>Written informed consent was obtained from all patients before inclusion in the study. </plain></SENT>
</text></p></sec><sec id="s4_2"><title><text><SENT sid="577" pm="."><plain>Patients </plain></SENT>
</text></title><p><text><SENT sid="578" pm="."><plain>All patients were enrolled from Peking University Cancer Hospital. </plain></SENT>
<SENT sid="579" pm="."><plain>Eligible patients had locally inoperable or metastatic, histologically confirmed diagnosis of NEC (Ki-67 index &gt; 20% and/or mitotic count exceeding 20/10 HPF), including mixed adenoneuroendocrine carcinoma (MANEC) if the gland-forming elements exceed 30%, with a gastroenteropancreatic primary or an unknown primary tumor predominantly with gastroenteropancreatic metastases. </plain></SENT>
<SENT sid="580" pm="."><plain>Additional inclusion criteria consisted of a Karnofsky performance score (KPS) ≥70; at least one radiologically measurable lesion; no previous chemotherapy and adequate bone marrow function; adequate hepatic and renal function; a life expectancy≥90 days; and ≥18 years of age. </plain></SENT>
<SENT sid="581" pm="."><plain>The exclusion criteria consisted of pregnant or nursing women, uncontrolled severe diarrhea, confirmed or suspected central nervous system metastasis, and a history of myocardial infarction within the past 6 months. </plain></SENT>
</text></p><p><text><SENT sid="582" pm="."><plain>In 2013, a Chinese pathologic consensus group for gastrointestinal and pancreatic neuroendocrine neoplasms proposed a new entity called “high proliferation neuroendocrine tumor (NET)”, which is defined as well differentiated neuroendocrine neoplasms with a Ki-67 level between 20-60% [24]. </plain></SENT>
<SENT sid="583" pm="."><plain>All of the GEP-NEC tumors in this study were re-reviewed by two pathologists independently for the new classification. </plain></SENT>
</text></p></sec><sec id="s4_3"><title><text><SENT sid="584" pm="."><plain>Pretreatment evaluation </plain></SENT>
</text></title><p><text><SENT sid="585" pm="."><plain>Pre-treatment evaluations included documentation of a routine history, a physical examination, KPS, a complete blood count (CBC), a chemistry profile, measurement of neuron-specific enolase (NSE) and electrocardiography. </plain></SENT>
<SENT sid="586" pm="."><plain>Tumor staging with computed tomography (CT) scans of the chest and abdomen was required. </plain></SENT>
<SENT sid="587" pm="."><plain>A magnetic resonance imaging (MRI) scan of the head and octreotide scanning were also required. </plain></SENT>
<SENT sid="588" pm="."><plain>A bone scan was indicated if the presence of bone metastases was clinically suspected. </plain></SENT>
</text></p></sec><sec id="s4_4"><title><text><SENT sid="589" pm="."><plain>Treatment </plain></SENT>
</text></title><p><text><SENT sid="590" pm="."><plain>All patients received combination chemotherapy with irinotecan (180 mg/m2) administered for 90 minutes by intravenous (IV) infusion (day 1) and cisplatin (50 mg/m2) administered for 120 minutes by IV infusion (day 1). </plain></SENT>
<SENT sid="591" pm="."><plain>The treatment courses were repeated every 2 weeks. </plain></SENT>
<SENT sid="592" pm="."><plain>This regimen required hydration and prophylactic administration of antiemetic drugs. </plain></SENT>
<SENT sid="593" pm="."><plain>If a patient's neutrophil count was ≤1.0×10^9/L, recombinant human granulocyte colony-stimulating factor (G-CSF) was administered until the neutrophil level was restored. </plain></SENT>
</text></p><p><text><SENT sid="594" pm="."><plain>Responses to treatment were assessed every 6 weeks. </plain></SENT>
<SENT sid="595" pm="."><plain>Patients who had an objective response or stable disease would receive an additional three cycles of chemotherapy. </plain></SENT>
<SENT sid="596" pm="."><plain>Patients who had an objective response or stable disease after chemotherapy were treated with octreotide LAR (20 mg, deep intramuscular injection) administered at 4-week intervals. </plain></SENT>
<SENT sid="597" pm="."><plain>The responses to octreotide LAR maintenance treatment were assessed every twelve weeks. </plain></SENT>
<SENT sid="598" pm="."><plain>Octreotide LAR was discontinued in cases of unacceptable toxicity, evidence of disease progression or patient refusal. </plain></SENT>
</text></p></sec><sec id="s4_5"><title><text><SENT sid="599" pm="."><plain>Evaluation of the treatment response </plain></SENT>
</text></title><p><text><SENT sid="600" pm="."><plain>Serial tumor assessments, based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.0), were performed every 6 weeks of treatment with a CT scan of the chest and abdomen with or without a scan of the pelvis. </plain></SENT>
<SENT sid="601" pm="."><plain>After discontinuation of the treatment, routine re-assessment at 6- to 8-week intervals was required for patients who withdrew from the study for reasons other than disease progression. </plain></SENT>
</text></p></sec><sec id="s4_6"><title><text><SENT sid="602" pm="."><plain>Dose modifications </plain></SENT>
</text></title><p><text><SENT sid="603" pm="."><plain>Toxicity was graded using the National Cancer Institution (NCI) Common Toxicity Criteria Version 3.0 (CTC 3.0) by direct questioning, physical examination, measurement of the CBC, and laboratory tests. </plain></SENT>
<SENT sid="604" pm="."><plain>Chemotherapy was withdrawn until the neutrophil count was ≥1.5×10^9/L, the platelet count was ≥100×10^9/L, diarrhea stopped and other toxicities recovered to ≤grade 1. </plain></SENT>
<SENT sid="605" pm="."><plain>The dose of irinotecan in subsequent cycles was reduced to 75% of the planned dose if patients experienced grade 4 hematologic toxic effects or if grade 3 diarrhea developed. </plain></SENT>
<SENT sid="606" pm="."><plain>The dose of cisplatin was reduced to 75% of the planned dose in patients with grade 2 renal toxicity. </plain></SENT>
<SENT sid="607" pm="."><plain>Treatment was terminated in patients with grade 4 diarrhea, grade 3 or higher renal toxicity, grade 2 or higher pulmonary toxicity, or grade 3 or higher hepatic toxicity. </plain></SENT>
</text></p></sec><sec id="s4_7"><title><text><SENT sid="608" pm="."><plain>Statistical methods </plain></SENT>
</text></title><p><text><SENT sid="609" pm="."><plain>The predicted PFS was the determinant of sample size. </plain></SENT>
<SENT sid="610" pm="."><plain>On the basis of the varied estimates of the PFS in prior studies [13–15], a PFS of 3.5 months or less was not considered worthy of further investigation. </plain></SENT>
<SENT sid="611" pm="."><plain>The target enrollment of 32 patients would provide an 80% power to detect a 2-months improvement in PFS with one-sided α of 0.05 and enrollment and follow-up periods of 2.0 and 1.0 years, respectively. </plain></SENT>
<SENT sid="612" pm="."><plain>To ensure an adequate number of evaluable patients, a total of 40 patients were enrolled. </plain></SENT>
</text></p><p><text><SENT sid="613" pm="."><plain>SPSS (version 13.0) statistical software was used for the statistical analyses. </plain></SENT>
<SENT sid="614" pm="."><plain>The results are presented as descriptive statistics. </plain></SENT>
<SENT sid="615" pm="."><plain>The survival curves were generated using the Kaplan-Meier method. </plain></SENT>
</text></p></sec></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="616" pm="."><plain>We thank all patients and their families who participated in this study. </plain></SENT>
</text></text4fund></p></ack></SecTag><fn-group><fn fn-type="COI-statement"><p><text><SENT sid="617" pm="."><plain>CONFLICTS OF INTEREST </plain></SENT>
</text></p><p><text><SENT sid="618" pm="."><plain>The authors declare there are no conflicts of interest to disclose. </plain></SENT>
</text></p></fn></fn-group><SecTag type="REF"><ref-list><title>REFERENCES</title><ref id="R1"><text><SENT sid="619" pm="."><plain>1BosmanFTCarneiroFHrubanRHTheiseNDWHO classification of tumours of the digestive system4th edLyonIARC Press;2010 </plain></SENT>
</text></ref><ref id="R2"><text><SENT sid="620" pm="."><plain>2KorseCMTaalBGvan VelthuysenMLFVisserOIncidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of 2 decades of cancer registryEur J Cancer2013491975198323352435 </plain></SENT>
</text></ref><ref id="R3"><text><SENT sid="621" pm="."><plain>3YaoJCHassanMPhanADagohoyCLearyCMaresJEAbdallaEKFlemingJBVautheyJNRashidAEvansDBOne hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United StatesJ Clin Oncol2008263063307218565894 </plain></SENT>
</text></ref><ref id="R4"><text><SENT sid="622" pm="."><plain>4ChoMYKimJMSohnJHKimMJKimKMKimWHKimHKookMCParkDYLeeJHChangHJungESKimHKCurrent trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Korea 2000-2009: multicenter studyCancer Res Treat2012441576523091441 </plain></SENT>
</text></ref><ref id="R5"><text><SENT sid="623" pm="."><plain>5FraenkelMKimMFaggianoAde HerderWWValkGDIncidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literatureEndocr Relat Cancer201421R15316324322304 </plain></SENT>
</text></ref><ref id="R6"><text><SENT sid="624" pm="."><plain>6SorbyeHStrosbergJBaudinEKlimstraDSYaoJCGastroenteropancreatic high-grade neuroendocrine carcinomaCancer20141202814282324771552 </plain></SENT>
</text></ref><ref id="R7"><text><SENT sid="625" pm="."><plain>7SorbyeHWelinSLangerSWVestermarkLWHoltNOsterlundPDuelandSHofsliEGurenMGOhrlingKBirkemeyerEThiis-EvensenEBiaginiMPredictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC studyAnn Oncol20132415216022967994 </plain></SENT>
</text></ref><ref id="R8"><text><SENT sid="626" pm="."><plain>8Surveillance, Epidemiology, and End Results (SEER) Program (<ext-link ext-link-type="uri" xlink:href="http://www.seer.cancer.gov">www.seer.cancer.gov</ext-link>)SEER*Stat Database: Incidence—SEER 9 Regs Research Data, November 2011 submission (1973-2010)Bethesda, MDNational Cancer Institute, Cancer Statistics Branch2013 </plain></SENT>
</text></ref><ref id="R9"><text><SENT sid="627" pm="."><plain>9StrosbergJRCoppolaDKlimstraDSPhanATKulkeMHWisemanGAKvolsLKNorth American Neuroendocrine Tumor Society (NANETS). </plain></SENT>
<SENT sid="628" pm="."><plain>The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomasPancreas20103979980020664477 </plain></SENT>
</text></ref><ref id="R10"><text><SENT sid="629" pm="."><plain>10ErikssonBAnnibaleBBajettaEMitryEPavelMPlataniaMSalazarRPlöckingerUMallorca Consensus Conference participants; European Neuroendocrine Tumor Society. </plain></SENT>
<SENT sid="630" pm="."><plain>ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumorsNeuroendocrinology20099021421919713713 </plain></SENT>
</text></ref><ref id="R11"><text><SENT sid="631" pm="."><plain>11National Comprehensive Cancer Network (NCCN)NCCN small cell lung cancer clinical practice guidelines in oncology (version 1.2016) [EB/OL]Fort WashingtonNCCN,2015 [06/02/15]<ext-link ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/f_guidelines.asp">http://www.nccn.org/professionals/physician_gls/f_guidelines.asp</ext-link>. </plain></SENT>
</text></ref><ref id="R12"><text><SENT sid="632" pm="."><plain>12JansonETSorbyeHWelinSFederspielBGrønbækHHellmanPLadekarlMLangerSWMortensenJSchalin-JänttiCSundinASundlövAThiis-EvensenEKniggeUNordic Guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasmsActa Oncol2014531284129725140861 </plain></SENT>
</text></ref><ref id="R13"><text><SENT sid="633" pm="."><plain>13MoertelCGKvolsLKO’ConnellMJRubinJTreatment of neuroendocrine carcinomas with combined etoposide and cisplatin. </plain></SENT>
<SENT sid="634" pm="."><plain>Evidence of major therapeutic activity in the anaplastic variants of these neoplasmsCancer1991682272321712661 </plain></SENT>
</text></ref><ref id="R14"><text><SENT sid="635" pm="."><plain>14MitryEBaudinEDucreuxMSabourinJCRufiéPAparicioTAparicioTLasserPEliasDDuvillardPSchlumbergerMRougierPTreatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatinBr J Cancer1999811351135510604732 </plain></SENT>
</text></ref><ref id="R15"><text><SENT sid="636" pm="."><plain>15IwasaSMorizaneCOkusakaTUenoHIkedaMKondoSTanakaTNakachiKMitsunagaSKojimaYHagiharaAHiraokaNCisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreasJpn J Clin Oncol20104031331820047862 </plain></SENT>
</text></ref><ref id="R16"><text><SENT sid="637" pm="."><plain>16NodaKNishiwakiYKawaharaMNegoroSSugiuraTYokoyamaAFukuokaMMoriKWatanabeKTamuraTYamamotoSSaijoNJapan Clinical Oncology GroupIrinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancerN Engl J Med2002346859111784874 </plain></SENT>
</text></ref><ref id="R17"><text><SENT sid="638" pm="."><plain>17LuZHLiJLuMZhangXTLiJZhouJWangXCGongJFGaoJLiYShenLFeasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomasMed Oncol20133066423864251 </plain></SENT>
</text></ref><ref id="R18"><text><SENT sid="639" pm="."><plain>18Chung-DelgadoKRevilla-MontagAGuillén-BravoSRíos-DíazHAlva-MuñozJCRefractory thrombocytopenia responds to octreotide treatment in a case of evans syndrome with gastric neuroendocrine tumorCase Rep Hematol2013201339108623984123 </plain></SENT>
</text></ref><ref id="R19"><text><SENT sid="640" pm="."><plain>19O’TooleDDucreuxMBommelaerGWemeauJLBouchéOCatusFBlumbergJRuszniewskiPTreatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and toleranceCancer20008877077610679645 </plain></SENT>
</text></ref><ref id="R20"><text><SENT sid="641" pm="."><plain>20VillaumeKBlancMGouysseGWalterTCoudercCNejjariMVercheratCCordier-BussatMRocheCScoazecJYVEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathwayNeuroendocrinology20109126827820389030 </plain></SENT>
</text></ref><ref id="R21"><text><SENT sid="642" pm="."><plain>21TomassettiPMiglioriMCorinaldesiRGulloLTreatment of gastroenteropancreatic neuroendocrine tumours with octreotide LARAliment Pharmacol Ther20001455756010792118 </plain></SENT>
</text></ref><ref id="R22"><text><SENT sid="643" pm="."><plain>22DucreuxMRuszniewskiPChayvialleJABlumbergJCloarecDMichelHRaymondJMDupasJLGouerouHJianRGenestinEHammelPRougierPThe antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumorsAm J Gastroenterol2000953276328111095353 </plain></SENT>
</text></ref><ref id="R23"><text><SENT sid="644" pm="."><plain>23RinkeAMüllerHHSchade-BrittingerCKloseKJBarthPWiedMMayerCAminossadatiBPapeUFBläkerMHarderJArnoldCGressTPlacebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study GroupJ Clin Oncol2009274656466319704057 </plain></SENT>
</text></ref><ref id="R24"><text><SENT sid="645" pm="."><plain>24Chinese pathologic consensus group for gastrointestinal and pancreatic neuroendocrine neoplasms. </plain></SENT>
<SENT sid="646" pm="."><plain>Standardization in diagnosis of gastrointestinal and pancreatic neuroendocrine neoplasms: the Chinese consensusZhonghua Bing Li Xue Za Zhi20134269169424439254 </plain></SENT>
</text></ref><ref id="R25"><text><SENT sid="647" pm="."><plain>25YamaguchiTMachidaNMorizaneCKasugaATakahashiHSudoKNishinaTTobimatsuKIshidoKFuruseJBokuNOkusakaTMulticenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive systemCancer Sci20141051176118124975505 </plain></SENT>
</text></ref><ref id="R26"><text><SENT sid="648" pm="."><plain>26SusiniCBuscailLRationale for the use of somatostatin analogs as antitumor agentsAnn Oncol2006171733174216801334 </plain></SENT>
</text></ref><ref id="R27"><text><SENT sid="649" pm="."><plain>27ME1CaplinPavelMĆwikłaJBPhanATRadererMSedláčkováECadiotGWolinEMCapdevilaJWallLRindiGLangleyAMartinezSLanreotide in metastatic enteropancreatic neuroendocrine tumorsN Engl J Med20143712243325014687 </plain></SENT>
</text></ref><ref id="R28"><text><SENT sid="650" pm="."><plain>28ZarogoulidisKEleftheriadouEKontakiotisTGerasimouGZarogoulidisPSapardanisIGalaktidouGSakkasLGotzamani-PsarrakouAKaratzasNLong acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patientsLung Cancer201276848 </plain></SENT>
</text></ref><ref id="R29"><text><SENT sid="651" pm="?"><plain>29ScoazecJYCouvelardAMongesGLeteurtreEBelleanneeGGuyetantSDuvillardPDanjouxMParotXLepageCWell-differentiated grade 3 digestive neuroendocrine tumors: myth or reality? </plain></SENT>
<SENT sid="652" pm="."><plain>The PRONET Study Group [abstract]J Clin Oncol20123015s(suppl; abstr 4129). </plain></SENT>
</text></ref><ref id="R30"><text><SENT sid="653" pm="."><plain>30Vélayoudom-CéphiseFLDuvillardPFoucanLHadouxJChougnetCNLeboulleuxSMalkaDGuigayJGoereDDebaereTCaramellaCSchlumbergerMPlanchardDAre G3 ENETS neuroendocrine neoplasms heterogeneous?Endocr Relat Cancer20132064965723845449 </plain></SENT>
</text></ref><ref id="R31"><text><SENT sid="654" pm="."><plain>31La RosaSSessaFHigh-grade poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: from morphology to proliferation and backEndocr Pathol20142519319824715269 </plain></SENT>
</text></ref><ref id="R32"><text><SENT sid="655" pm="."><plain>32OlsenIHSørensenJBFederspielBKjaerAHansenCPKniggeULangerSWTemozolomide as second or third line treatment of patients with neuroendocrine carcinomasScientific World Journal2012201217049622973169 </plain></SENT>
</text></ref><ref id="R33"><text><SENT sid="656" pm="."><plain>33FonsecaPJUriolEGalvánJAAlvarezCPérezQVillanuevaNBerrosJPIzquierdoMViéitezJMProlonged clinical benefit of Everolimus therapy in the management of high-grade pancreatic neuroendocrine carcinomaCase Rep Oncol2013644144924019785 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
